Sandu Pharmaceuticals Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 764862,
    "name": "Sandu Pharma.",
    "stock_name": "Sandu Pharma.",
    "full_name": "Sandu Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/sandu-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "34.00",
    "chg": -0.7,
    "chgp": "-2.02%",
    "dir": -1,
    "prev_price": "34.70",
    "mcapval": "33.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524703,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 49,
    "indexname": "",
    "isin": "INE751D01014",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "2.12 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/sandu-pharma-764862-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.01 Amidst Market Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-stock-falls-to-52-week-low-of-rs3701-3735027",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanduPharmaceut_priceRelatedfactors_3735027.png",
        "date": "2025-11-28 09:48:44",
        "description": "Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.01 today, marking a significant decline in its stock price amid broader market activity. The stock’s performance contrasts with the overall positive trend in the Sensex, highlighting ongoing challenges within the company’s financial and operational metrics."
      },
      {
        "title": "Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.01 Amidst Continued Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-stock-falls-to-52-week-low-of-rs3701-3735029",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanduPharmaceut_priceRelatedfactors_3735029.png",
        "date": "2025-11-28 09:48:30",
        "description": "Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.01 today, marking a significant decline in its stock price amid ongoing challenges in its financial performance and market positioning within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.21 Amid Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-stock-hits-52-week-low-amidst-continued-downtrend-3729278",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanduPharmaceut_priceRelatedfactors_3729278.png",
        "date": "2025-11-25 15:42:29",
        "description": "Sandu Pharmaceuticals touched a fresh 52-week low of Rs.37.21 today, marking a significant decline amid a sustained downward trend. The stock has recorded losses over the past three consecutive sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.21 Amid Market Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-stock-falls-to-52-week-low-of-rs3721-3729276",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanduPharmaceut_priceRelatedfactors_3729276.png",
        "date": "2025-11-25 15:42:28",
        "description": "Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.21 today, marking a significant decline amid broader market fluctuations and sector underperformance. The stock has experienced a notable downward trend over the past three days, reflecting ongoing challenges within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Why is Sandu Pharma. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-sandu-pharma-fallingrising-3726673",
        "imagepath": "",
        "date": "2025-11-25 00:39:41",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Sandu Pharmaceuticals’ share price rose by ₹0.48, or 1.2%, on 24 November, signalling a positive session for the stock. This gain is notable given the broader context of the stock’s performance, which has been under pressure for an extended period. Over the past week, the stock has declined by 5.46%, significantly underperforming the Sensex, which remained almost flat with a marginal 0.06% loss. The one-month trend also shows a decline of 8.25%, contrasting with the Sensex’s 0.82% gain. These figures highlight the stock’s recent weakness relative to the broader market.</p>\n<p>Year-to-date, Sandu Pharmaceuticals has seen a steep fall of 29.29%, while the Sensex has advanced by 8.65%. Over the last year, the stock’s decline of 28.70% sta..."
      },
      {
        "title": "Is Sandu Pharma. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-sandu-pharma-overvalued-or-undervalued-3716743",
        "imagepath": "",
        "date": "2025-11-20 08:06:19",
        "description": "As of 19 November 2025, Sandu Pharma's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 25.21, an EV to EBITDA of 13.51, and a Price to Book Value of 0.94, which suggest that the stock is trading at a reasonable price relative to its earnings and book value.\n\nIn comparison to its peers, Sandu Pharma's valuation appears favorable. For instance, Elitecon International is categorized as very expensive with a PE Ratio of 265.8, while PTC India, deemed very attractive, has a significantly lower PE Ratio of 7.5. Despite recent underperformance, with a year-to-date return of -28.92% compared to the Sensex's 9.02%, the attractive valuation grade and competitive ratios position Sandu Pharma as a potential buying opportunity in the pharmaceuticals and b..."
      },
      {
        "title": "Why is Sandu Pharma. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-sandu-pharma-fallingrising-3712899",
        "imagepath": "",
        "date": "2025-11-18 22:04:02",
        "description": "As of 18-Nov, Sandu Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs. 41.78, which represents a decrease of Rs. 1.05 or 2.45%. The stock has hit a new 52-week low of Rs. 38 today, reflecting a significant drop of 11.28% at its intraday low. Over the past week, the stock has underperformed its sector by 1.89% and has seen a consecutive fall over the last two days, accumulating a total decline of 3.98%. Additionally, the stock is trading below its moving averages across various time frames, indicating a bearish trend. There has also been a notable decrease in investor participation, with delivery volume dropping by 71.14% compared to the five-day average, which further suggests weakening investor interest.\n\nIn the broader market context, Sandu Pharmaceuticals has underperformed significantly compared to the Sensex, with a year-to-date return of -27.03% against the benchmark's ..."
      },
      {
        "title": "Sandu Pharmaceuticals Falls to 52-Week Low of Rs.38 Amidst Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-falls-to-52-week-low-of-rs38-on-18-nov-2025-3711956",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanduPharmaceut_priceRelatedfactors_3711956.png",
        "date": "2025-11-18 13:28:25",
        "description": "Sandu Pharmaceuticals has reached a new 52-week low of Rs.38, marking a significant decline in its stock price amid ongoing downward momentum. The stock has underperformed its sector and benchmark indices, reflecting persistent challenges in its financial performance and market positioning."
      },
      {
        "title": "Sandu Pharmaceuticals Stock Plummets to New 52-Week Low at Rs. 40.21",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-stock-plummets-to-new-52-week-low-at-rs-4021-3707267",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanduPharmaceut_priceRelatedfactors_3707267.png",
        "date": "2025-11-17 11:09:47",
        "description": "Sandu Pharmaceuticals has hit a new 52-week low, reflecting a significant decline in its stock performance. The company has underperformed its sector and experienced a notable drop over the past year. Financial metrics indicate challenges, including low Return on Equity and concerns regarding debt management."
      }
    ],
    "total": 78,
    "sid": "764862",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/sandu-pharmaceuticals-764862"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Approval Of Unaudited Financial Results For Q Ended 31St December 2025",
      "datetime": "24-Jan-2026",
      "details": "Sandu Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 inter alia to consider and approve 1.approval of Unaudited Financial Results for Q ended 31st December 2025 2. any other matter with permission of Chairman",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "07-Jan-2026",
      "details": "Certificate under Regulation 74(5) of SEBI (DP) Regulation 2015 for Q ended 31.12.2025",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "24-Dec-2025",
      "details": "Intimation about the closure of trading window for Q ended 31st December 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Sandu Pharmaceuticals Ltd has declared <strong>8%</strong> dividend, ex-date: 18 Sep 25",
          "dt": "2025-09-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.01 Amidst Market Pressure

2025-11-28 09:48:44

Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.01 today, marking a significant decline in its stock price amid broader market activity. The stock’s performance contrasts with the overall positive trend in the Sensex, highlighting ongoing challenges within the company’s financial and operational metrics.

Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.01 Amidst Continued Underperformance

2025-11-28 09:48:30

Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.01 today, marking a significant decline in its stock price amid ongoing challenges in its financial performance and market positioning within the Pharmaceuticals & Biotechnology sector.

Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.21 Amid Continued Downtrend

2025-11-25 15:42:29

Sandu Pharmaceuticals touched a fresh 52-week low of Rs.37.21 today, marking a significant decline amid a sustained downward trend. The stock has recorded losses over the past three consecutive sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Sandu Pharmaceuticals Falls to 52-Week Low of Rs.37.21 Amid Market Pressure

2025-11-25 15:42:28

Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.21 today, marking a significant decline amid broader market fluctuations and sector underperformance. The stock has experienced a notable downward trend over the past three days, reflecting ongoing challenges within the Pharmaceuticals & Biotechnology sector.

Why is Sandu Pharma. falling/rising?

2025-11-25 00:39:41

Recent Price Movement and Market Context Sandu Pharmaceuticals’ share price rose by ₹0.48, or 1.2%, on 24 November, signalling a positive session for the stock. This gain is notable given the broader context of the stock’s performance, which has been under pressure for an extended period. Over the past week, the stock has declined by 5.46%, significantly underperforming the Sensex, which remained almost flat with a marginal 0.06% loss. The one-month trend also shows a decline of 8.25%, contrasting with the Sensex’s 0.82% gain. These figures highlight the stock’s recent weakness relative to the broader market. Year-to-date, Sandu Pharmaceuticals has seen a steep fall of 29.29%, while the Sensex has advanced by 8.65%. Over the last year, the stock’s decline of 28.70% sta...

Is Sandu Pharma. overvalued or undervalued?

2025-11-20 08:06:19

As of 19 November 2025, Sandu Pharma's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 25.21, an EV to EBITDA of 13.51, and a Price to Book Value of 0.94, which suggest that the stock is trading at a reasonable price relative to its earnings and book value. In comparison to its peers, Sandu Pharma's valuation appears favorable. For instance, Elitecon International is categorized as very expensive with a PE Ratio of 265.8, while PTC India, deemed very attractive, has a significantly lower PE Ratio of 7.5. Despite recent underperformance, with a year-to-date return of -28.92% compared to the Sensex's 9.02%, the attractive valuation grade and competitive ratios position Sandu Pharma as a potential buying opportunity in the pharmaceuticals and b...

Why is Sandu Pharma. falling/rising?

2025-11-18 22:04:02

As of 18-Nov, Sandu Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs. 41.78, which represents a decrease of Rs. 1.05 or 2.45%. The stock has hit a new 52-week low of Rs. 38 today, reflecting a significant drop of 11.28% at its intraday low. Over the past week, the stock has underperformed its sector by 1.89% and has seen a consecutive fall over the last two days, accumulating a total decline of 3.98%. Additionally, the stock is trading below its moving averages across various time frames, indicating a bearish trend. There has also been a notable decrease in investor participation, with delivery volume dropping by 71.14% compared to the five-day average, which further suggests weakening investor interest. In the broader market context, Sandu Pharmaceuticals has underperformed significantly compared to the Sensex, with a year-to-date return of -27.03% against the benchmark's ...

Sandu Pharmaceuticals Falls to 52-Week Low of Rs.38 Amidst Continued Downtrend

2025-11-18 13:28:25

Sandu Pharmaceuticals has reached a new 52-week low of Rs.38, marking a significant decline in its stock price amid ongoing downward momentum. The stock has underperformed its sector and benchmark indices, reflecting persistent challenges in its financial performance and market positioning.

Sandu Pharmaceuticals Stock Plummets to New 52-Week Low at Rs. 40.21

2025-11-17 11:09:47

Sandu Pharmaceuticals has hit a new 52-week low, reflecting a significant decline in its stock performance. The company has underperformed its sector and experienced a notable drop over the past year. Financial metrics indicate challenges, including low Return on Equity and concerns regarding debt management.

View All News